骨肉瘤预后相关基因的研究进展  

Research progress of genes related to prognosis of osteosarcoma

作　　者：张小波 史桂霞 曹恒 王剑龙[1] Zhang Xiaobo;Shi Guixia;Cao Heng;Wang Jianlong(Department of Spine Surgery,The Third Xiangya Hospital of Central South University,Changsha 410000,China;Health Vocational College of Changsha,Changsha 410000,China;Department of Orthopaedics,Affiliated Hospital of Yiyang Medical College,Yiyang 413000,China)

机构地区：[1]中南大学湘雅三医院脊柱外科,长沙410000 [2]长沙卫生职业学院,长沙410000 [3]益阳医专附属医院骨科,益阳413000

出　　处：《中国综合临床》2022年第3期279-284,共6页Clinical Medicine of China

摘　　要：骨肉瘤是一种起源于间充质组织的原发性恶性肿瘤, 主要发生在儿童和青少年, 具有恶性程度高、生长快、转移早及预后差等特点。目前国内外大部分研究主要集中于早期诊断和治疗上。然而, 可靠的预测指标对于监测疾病变化、指导治疗和评估预后至关重要。近几年关于骨肉瘤预后相关基因的研究已成为新的热点, 其异常表达影响骨肉瘤细胞的进展、侵袭和转移等过程, 在骨肉瘤的耐药性及化疗中均发挥重要作用。现就影响骨肉瘤预后相关的基因:miRNAs、lncRNA、CircRNA、ErbB基因家族的异常表达及癌基因、免疫相关基因的失调做简要概括, 充分的了解其特征, 以期为骨肉瘤患者的早期诊断和治疗提供一种新方向和可能新的药物治疗靶点, 从而达到改善骨肉瘤患者预后的目的。Osteosarcoma is a kind of primary malignant tumor of bone originated from mesenchymal tissue,which mainly occurs in children and adolescents,and presents the characteristics of high malignancy,rapid growth,early metastasis and poor prognosis.Currently,most of the studies at home and abroad mainly focused on therapeutic procedures.However,reliable predictors are essential for monitoring disease changes,guiding treatment and evaluating prognosis.In recent years,the research on prognosis related genes of osteosarcoma has become a new hotspot.Its abnormal expression affects the progress,invasion and metastasis of osteosarcoma cells,and plays an important role in drug resistance and chemotherapy of osteosarcoma.This paper briefly summarizes the abnormal expression of genes related to the prognosis of osteosarcoma:miRNAs,Incrna,CircRNA,ErbB gene family and the imbalance of oncogenes and immune related genes,and fully understands their characteristics,in order to provide a new direction and possible new drug treatment target for the early diagnosis and treatment of osteosarcoma patients,so as to improve the prognosis of osteosarcoma patients.

关 键 词：骨肉瘤 预后 基因 

分 类 号：R738.1[医药卫生—肿瘤]